Drug Profile
Clostridium difficile immune globulin - Immuron
Alternative Names: DiffGAM™; IMM308Latest Information Update: 23 Jan 2015
Price :
$50
*
At a glance
- Originator ImmuCell
- Developer Immuron
- Class Antibacterials; Immunoglobulins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Clostridium difficile infections
Most Recent Events
- 23 Jan 2015 Discontinued - Phase-II for Clostridium difficile infections in Australia (PO)
- 30 Sep 2010 Phase-II clinical trials in Clostridium difficile infections in Australia (PO)
- 15 Jan 2003 DiffGAM technology has been licensed to CURx outside of Europe and certain nutritional rights in North America (www.curxpharma.com)